Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LGVN is expected to report earnings to fall 21.05% to -15 cents per share on November 06
Q3'26
Est.
$-0.15
Q2'26
Missed
by $0.01
Q1'26
Beat
by $0.13
Q4'25
Missed
by $0.04
Q3'25
Missed
by $0.18
The last earnings report on August 12 showed earnings per share of -18 cents, missing the estimate of -18 cents. With 389.52K shares outstanding, the current market capitalization sits at 26.94M.